Combined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction
Daniel Lindholm, Giovanna Sarno, David Erlinge, Bodil Svennblad, Lars Pål Hasvold, Magnus Janzon, Tomas Jernberg, Stefan K James, Daniel Lindholm, Giovanna Sarno, David Erlinge, Bodil Svennblad, Lars Pål Hasvold, Magnus Janzon, Tomas Jernberg, Stefan K James
Abstract
Objective: In patients with myocardial infarction (MI), risk factors for bleeding and ischaemic events tend to overlap, but the combined effects of these factors have scarcely been studied in contemporary real-world settings. We aimed to assess the combined associations of established risk factors using nationwide registries.
Methods: Using the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, patients with invasively managed MI in 2006-2014 were included. Six factors were assessed in relation to cardiovascular death (CVD)/MI/stroke, and major bleeding: age ≥65, chronic kidney disease, diabetes, multivessel disease, prior bleeding and prior MI.
Results: We studied 100 879 patients, of whom 20 831 (20.6%) experienced CVD/MI/stroke and 5939 (5.9%) major bleeding, during 3.6 years median follow-up. In adjusted Cox models, all factors were associated with CVD/MI/stroke, and all but prior MI were associated with major bleeding. The majority (53.5%) had ≥2 risk factors. With each added risk factor, there was a marked but gradual increase in incidence of the CVD/MI/stroke. This was seen also for major bleeding, but to a lesser extent, largely driven by prior bleeding as the strongest risk factor.
Conclusions: The majority of patients with MI had two or more established risk factors. Increasing number of risk factors was associated with higher rate of ischaemic events. When excluding patients with prior major bleeding, bleeding incidence rate increased only minimally with increasing number of risk factors. The high ischaemic risk in those with multiple risk factors highlights an unmet need for additional preventive measures.
Keywords: acute coronary syndromes; risk factors.
Conflict of interest statement
Competing interests: DL reports being an employee at Uppsala University and affiliated with Uppsala Clinical Research Center during the time this work was conducted, but has since been employed by AstraZeneca. BS reports institutional research grants from AstraZeneca, Novartis and Abbott. LPH reports being employed by AstraZeneca. MJ reports lecture fees from AstraZeneca and Pfizer. TJ has received consultant and lecture fees from AstraZeneca, MSD and Aspen. SKJ reports institutional research grants from AstraZeneca.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Figures
References
- Wallentin L, Becker RC, Budaj A, et al. . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–57. 10.1056/NEJMoa0904327
- Wiviott SD, Braunwald E, McCabe CH, et al. . Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15. 10.1056/NEJMoa0706482
- Bonaca MP, Bhatt DL, Cohen M, et al. . Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791–800. 10.1056/NEJMoa1500857
- Eikelboom JW, Connolly SJ, Bosch J, et al. . Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017;377:1319–30. 10.1056/NEJMoa1709118
- Yeh RW, Secemsky EA, Kereiakes DJ, et al. . Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA 2016;315:1735–49. 10.1001/jama.2016.3775
- Lindholm D, James SK, Bertilsson M, et al. . Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clin Chem 2017;63:573–84. 10.1373/clinchem.2016.261271
- Yusuf S, Hawken S, Ounpuu S, et al. . Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–52. 10.1016/S0140-6736(04)17018-9
- Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. . Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. The Lancet 2013;382:339–52. 10.1016/S0140-6736(13)60595-4
- Smolina K, Wright FL, Rayner M, et al. . Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes 2012;5:532–40. 10.1161/CIRCOUTCOMES.111.964700
- Anand SS, Islam S, Rosengren A, et al. . Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008;29:932–40. 10.1093/eurheartj/ehn018
- Jernberg T, Attebring MF, Hambraeus K, et al. . The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart 2010;96:1617–21. 10.1136/hrt.2010.198804
- Friberg L, Skeppholm M. Usefulness of Health Registers for detection of bleeding events in outcome studies. Thromb Haemost 2016;116:1131–9. 10.1160/TH16-05-0400
- Mauri L, Kereiakes DJ, Yeh RW, et al. . Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155–66. 10.1056/NEJMoa1409312
- Bansilal S, Bonaca MP, Cornel JH, et al. . Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. J Am Coll Cardiol 2018;71:489–96. 10.1016/j.jacc.2017.11.050
- Ahlqvist E, Storm P, Käräjämäki A, et al. . Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018;6:361–9. 10.1016/S2213-8587(18)30051-2
- Valgimigli M, Bueno H, Byrne RA, et al. . 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213–60. 10.1093/eurheartj/ehx419
- Costa F, van Klaveren D, James S, et al. . Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;389:1025–34. 10.1016/S0140-6736(17)30397-5
- Lindholm D, Hagström E, James SK, et al. . Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. J Am Heart Assoc 2017;6 10.1161/JAHA.117.005580
- Ludvigsson JF, Andersson E, Ekbom A, et al. . External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450 10.1186/1471-2458-11-450
Source: PubMed